Related Experiment Video

Updated: Apr 18, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K

[Cytogenetic abnormalities in high-risk multiple myeloma].

Tadao Ishida

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |January 29, 2015
    PubMed
    Summary

    Multiple myeloma subtypes have distinct genetic features. Specific genetic lesions like del(17p13) and IgH translocations, along with ERK pathway mutations, significantly impact patient survival and disease progression in multiple myeloma.

    Area of Science:

    • Hematology
    • Oncology
    • Cancer Genetics

    More Related Videos

    Chromosome Preparation From Cultured Cells
    07:42

    Chromosome Preparation From Cultured Cells

    Published on: January 28, 2014

    84.6K
    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
    14:51

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

    Published on: June 17, 2022

    3.7K

    Related Experiment Videos

    Last Updated: Apr 18, 2026

    Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
    07:53

    Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

    Published on: April 15, 2022

    4.9K
    Chromosome Preparation From Cultured Cells
    07:42

    Chromosome Preparation From Cultured Cells

    Published on: January 28, 2014

    84.6K
    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
    14:51

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

    Published on: June 17, 2022

    3.7K

    Related Concept Videos

    Abnormal Proliferation02:23

    Abnormal Proliferation

    5.5K
    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    5.5K
    Induced Pluripotent Stem Cells01:06

    Induced Pluripotent Stem Cells

    6.4K
    Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
    Somatic...
    6.4K

    Articles linked to this work by shared authors, journal, and citation graph.

    Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

    Clinical hematology international·2026

    Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study.

    EJHaem·2026

    Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

    Transplantation and cellular therapy·2026

    Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

    Blood·2026

    Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

    Cells·2026

    A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database.

    Therapeutic advances in hematology·2026

    Clinical characteristics, surgical management, and outcomes of uterine smooth muscle tumours of uncertain malignant potential: a single-centre experience.

    Przeglad menopauzalny = Menopause review·2026

    BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.

    Health science reports·2026

    Classical Hodgkin Lymphoma Today.

    Mediterranean journal of hematology and infectious diseases·2026

    Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.

    Frontiers in pharmacology·2026

    LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

    Frontiers in pharmacology·2026

    Case Report: refractory hemophagocytic lymphohistiocytosis progression despite complete metabolic response in a patient with stage IV extranodal NK/T-cell lymphoma: clinical observation of "tumor-immune dissociation" phenomenon.

    Frontiers in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us